IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
also take on 140 Nektar per son nel, as well as cer tain in tel lec tual prop erty and man u fac tur ing meth ods.
Man u fac tur ing and roy alty rights to tobramycin inhaled powder (Inhaled Tobi) will be transferred to
Novartis.
July: It was re ported that Novartis has signed a deal with the Swiss firm Lonza to help it de velop and
man u fac ture new bi o log i cal prod ucts.
June: Sandoz of fi cially opened its global HQ build ing in Holzkirchen, Ger many, fol low ing in vest ment of
Euro35 mil lion ($55 bil lion).
May: Amedipharm (UK) ac quired rights to a num ber of older Novartis prod ucts out side the USA. These
are: Apresoline, Hygroton, Hygroton Re ser pine, Cafergot, Deseril, Dihydergot, Migranal, Tofranil,
Ludiomil, Locacorten, Locasalen and Sicorten.
April: Novartis ap pointed Lud wig Hantson as head of its US phar ma ceu ti cal busi ness.
• Year: 2007
Novartis launched the “For ward” ini tia tive to im prove com pet i tive ness. This ini tia tive will sim plify or ga ni -
za tional struc tures, ac cel er ate and de cen tral ize de ci sion-mak ing pro cesses, re de sign the way Novartis
op er ates and pro vide pro duc tiv ity gains. Pre-tax an nual cost sav ings of $1.6 bil lion are ex pected in 2010.
Ap prox i mately 2,500 full-time po si tions are ex pected to be re duced from among the cur rently nearly
100,000 full-time employees within the group.
Novartis an nounced the con struc tion of a $700 mil lion biotech man u fac tur ing fa cil ity in Sin ga pore. The
plant will con tain Novartis’ larg est bioreactor world wide. Once open, the new fa cil ity will em ploy 300 peo -
ple. Con struc tion will start in 2008 and com ple tion is expected in 2012.
Novartis sold its Gerber baby food busi ness for $5.5 bil lion in cash to Nes tle (Swit zer land).
• Year: 2006
Novartis an nounced the di vest ment of its med i cal nu tri tion busi ness to Nes tle for $2.5 bil lion.
Novartis an nounced plans to in vest $100 mil lion in a new drug dis cov ery fa cil ity in Shang hai.
Novartis an nounced plans to build the first cell cul ture-de rived in flu enza vac cines man u fac tur ing plant in
the US at a site in Holly Springs, North Carolina.
Novartis was one of a hand ful of com pa nies awarded mul ti mil lion dol lar con tracts by the US gov ern ment
to work on cell-based pro duc tion tech nol o gies as part of the gov ern ment’s avian-flu pan demic plan.
Novartis will use the $221 mil lion con tract to fund the con struc tion of a new cell-based plant in the US that
will sup ply the American market only.
Novartis set up a global R&D cen ter for OTC prod ucts in Thane, near Mumbai, In dia. The new fa cil ity will
de velop OTC prod ucts, par tic u larly in ar eas such as cough/cold, al ler gies, smok ing ces sa tion, gas tro in -
tes ti nal dis or ders, der mal in fec tions and nutritional supplements.
Novartis sold its Span ish generics unit, Uso Racional, to Pliva (Croatia) for Euro21.5 mil lion ($25.6 mil -
lion).
© 2009 IMS Health In cor po rated or its af fil i ates Page 143